Bis[2-(acetyloxy)benzoato]copper | 23325-63-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Bis[2-(acetyloxy)benzoato]copper
• 英文别名: copper;2-acetyloxybenzoate
• CAS: 23325-63-5
• 化学式: C18H14CuO8
• 分子量: 421.8
• InChiKey: CMDYHTIDHSNRGW-UHFFFAOYSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  -0.05
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  133
• 氢给体数：
  0
• 氢受体数：
  8

文献信息

• Pharmaceutical compositions for treating inflammation or arthritis
  申请人：NATIONAL RESEARCH LABORATORIES

  公开号：EP0115130A1

  公开（公告）日：1984-08-08

  The anti-inflammatory or anti-arthritic agent of this invention comprises a monometal complex of multivalent heavy metal and a polyfunctional organic ligand in a ratio of 1: 1 of the metal to the ligand, the complex having a dissociation property represented by a sigmoidally shaped plot on a pM-pH diagram. Specific examples of the metal complex are dialkali metal monocopper (II) citrates represented by disodium-, dipotassium- or dilithium-monocopper (II) citrate. These dialkali monocopper (II) citrates have a dissociation property represented by a sigmoidal plot, wherein the curve of two directions meet at a point within the pH range of about 7 to about 9.

  本发明的抗炎剂或抗关节炎剂包括多价重金属和多官能团有机配体的单金属络合物，金属和配体的比例为 1:1，络合物的解离特性在 pM-pH 图上呈乙型曲线。金属络合物的具体例子是以柠檬酸二钠、柠檬酸二钾或柠檬酸二锂为代表的二钾基金属单铜（II）柠檬酸盐。这些二碱单铜(II)柠檬酸盐的解离特性以西格玛图表示，其中两个方向的曲线在 pH 值约 7 到约 9 的范围内的某一点相交。
• Compounds and therapies for the prevention of vascular and non-vascular pathologies
  申请人：NeoRx Corporation

  公开号：US20030064970A1

  公开（公告）日：2003-04-03

  The invention provides a method of treating a mammal having, or at risk of, an indication associated with a TGF-beta deficiency comprising administering one or more agents that is effective to elevate the level of TGF-beta. The invention also provides novel compounds that elevate TGF-beta levels, as well as pharmaceutical compositions comprising compounds that elevate TGF-beta levels, and methods for detecting diseases associated with endothelial cell activation.

  本发明提供了一种治疗哺乳动物的方法，该哺乳动物具有或有可能具有与 TGF-beta 缺乏有关的适应症，该方法包括施用一种或多种能有效提高 TGF-beta 水平的制剂。本发明还提供了能提高TGF-beta水平的新型化合物、包含能提高TGF-beta水平的化合物的药物组合物，以及检测与内皮细胞活化相关的疾病的方法。
• COPPER COMPLEX FOR TREATING CANCER
  申请人：INTERNATIONAL COPPER ASSOCIATION, INC.

  公开号：EP0145711A1

  公开（公告）日：1985-06-26
• Novel Indications for Transforming Growth Factor-Beta Regulators
  申请人：Coussens Lisa M.

  公开号：US20080206219A1

  公开（公告）日：2008-08-28

  Methods, compounds and compositions for the modulation of TGF-β are disclosed wherein the vascular permeability in a subject is altered. The compounds can be antagonists or agonists, and can be oligonucleotides, antisense oligonucleotides, small molecules, antibodies, and the like. Compounds that modulate TGF-β, regulate TGF-β bioavailabililty, or the configuration and context of type 1 collagen can be used for the treatment or prevention of diseases caused by vascular permeability.
• US4657928A
  申请人：——

  公开号：US4657928A

  公开（公告）日：1987-04-14